MIRUM PHARMACEUTICALS, INC. (MIRM)
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
📈 **POSITIVE** • High confidence analysis (81%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business